Team:Yale/Results
From 2014.igem.org
Line 126: | Line 126: | ||
<td colspan="12"> | <td colspan="12"> | ||
<div class = "tinycall"> | <div class = "tinycall"> | ||
- | <h1> | + | <h1>T7 Riboregulation System</h1> |
</div> | </div> | ||
Line 133: | Line 133: | ||
<ol type="I"> | <ol type="I"> | ||
- | <li><strong> | + | <li><strong>T7 RNA polymerase design and creation</strong><p> |
- | + | The T7 Riboregulation System works by a “three-lock system.” The first lock is the cis- repressing RNA (crRNA), which is induced bysopropyl β-D-1-thiogalactopyranoside (IPTG). The second lock is the trans-activating RNA (taRNA), which is induced by anhydrous tetracycline (ATC). If the taRNA is unlocked, it will bind to the crRNA, removing the hairpin and making the ribosomal binding site accessible for ribosomal binding, leading to translation of a specific protein, in this case, T7 RNA Polymerase. This system was initially developed by Dr. Farren Isaacs, and has been shown to work with chloramphenicol resistance (chloramphenical acetyl transferase gene) in place of the T7 gene. The plasmid was synthesized via Gibson assembly, and confirmed by sequencing. | |
- | < | + | <img src="https://static.igem.org/mediawiki/2014/6/66/Yale_figure7.png"> |
+ | <p> | ||
+ | <center> | ||
+ | <i><strong>Figure 1.</strong> Preliminary gel screening of Mach 1 strains containing transformed pZE21_A12C_T7RNA plasmids created via Gibson Assembly.</i></center></p> | ||
- | < | + | <img src="https://static.igem.org/mediawiki/2014/f/f2/Yale_sequences_1.png"> |
+ | |||
+ | <p> | ||
+ | <center> | ||
+ | <i><strong>Figure 2.</strong> Sequencing data for T7 RNA polymerase construct, upstream of the taRNA and crRNA system. Image made using geneious.</i></center></p> | ||
+ | |||
+ | <p>Currently the riboregulation system may have an issue with the internal T7 sequence, and while sequencing has been done, no successful data has been obtained.</p> | ||
+ | |||
+ | |||
+ | <li><strong>Functional Assays for Riboregulated T7 system</strong> | ||
+ | <p>The P<sub>LlacO</sub> promoter controls the expression of the crRNA and is induced by IPTG. As specified above, we will use artificial riboregulatory elements to restrict translation of the mRNA sequence encoding the T7 RNA Polymerase. Specifically, the crRNA sequence will be inserted downstream of the promoter driving T7 RNA Polymerase and upstream of the ribosomal binding site (RBS). | ||
<p>A second promoter, P<sub>LtetO</sub>, which is induced by ATC, will express the taRNA capable of interacting with the crRNA and releasing the RBS for docking of the T7 RNA polymerase. This will expose the RBS and allow for translation of T7 RNA Polymerase. Once the T7 RNA Polymerase is expressed, it can then bind to the T7 Promoter and lead to the expression of the gene of interest, such as LL-37. The ribo-regulated T7 RNA Polymerase (formally known as α12c) and the TolC selection marker will be ultimately incorporated into a conjugative plasmid and into the genome of <i>E. coli</i> to control for copy number. In this way, the cell can better regulate protein expression. A second pZ plasmid will contain the gene of interest expressed by a T7 promoter. Finally, the third plasmid will contain the OTS. | <p>A second promoter, P<sub>LtetO</sub>, which is induced by ATC, will express the taRNA capable of interacting with the crRNA and releasing the RBS for docking of the T7 RNA polymerase. This will expose the RBS and allow for translation of T7 RNA Polymerase. Once the T7 RNA Polymerase is expressed, it can then bind to the T7 Promoter and lead to the expression of the gene of interest, such as LL-37. The ribo-regulated T7 RNA Polymerase (formally known as α12c) and the TolC selection marker will be ultimately incorporated into a conjugative plasmid and into the genome of <i>E. coli</i> to control for copy number. In this way, the cell can better regulate protein expression. A second pZ plasmid will contain the gene of interest expressed by a T7 promoter. Finally, the third plasmid will contain the OTS. | ||
<p>The benefit of this type of system is that it is robust and can be easily re-engineered, portable in the form of plasmids, compatible across multiple <i>E. coli</i> strains, and efficient in that it does not require the cell to expend more energy on the constitutive synthesis of another protein. We hypothesize that by utilizing these two levels of control, we will be able to reduce the expression of T7 RNA polymerase and produce a system with zero basal expression of the gene of interest.</p></ul> | <p>The benefit of this type of system is that it is robust and can be easily re-engineered, portable in the form of plasmids, compatible across multiple <i>E. coli</i> strains, and efficient in that it does not require the cell to expend more energy on the constitutive synthesis of another protein. We hypothesize that by utilizing these two levels of control, we will be able to reduce the expression of T7 RNA polymerase and produce a system with zero basal expression of the gene of interest.</p></ul> |
Revision as of 02:56, 18 October 2014
Results |
|||||||||||
T7 Riboregulation System
| |||||||||||
Adhesion Testing
|